stoxline Quote Chart Rank Option Currency Glossary
  
(DMD)
  0 (0%)    03-28 08:42
Open:
High:
Volume: 0
  
Pre. Close:
Low:
Market Cap: 0(M)
Technical analysis
2024-03-28 8:14:02 AM
Short term     
Mid term     
Targets 6-month :  102.39 1-year :  119.6
Resists First :  87.66 Second :  102.39
Pivot price 84.6
Supports First :  84.06 Second :  81.83
MAs MA(5) :  86.02 MA(20) :  84.34
MA(100) :  78.14 MA(250) :  70.81
MACD MACD :  0.9 Signal :  0.7
%K %D K(14,3) :  65.9 D(3) :  65.6
RSI RSI(14): 63.4
52-week High :  87.66 Low :  58.75
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ DDM ] has closed below upper band by 5.8%. Bollinger Bands are 4.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 87.04 - 87.57 87.57 - 88.07
Low: 84.41 - 85.03 85.03 - 85.63
Close: 86.04 - 86.96 86.96 - 87.84
Company Description

Headline News

Thu, 28 Mar 2024
Elixirgen Therapeutics' Bobcat mRNA Therapeutic for Duchenne Muscular Dystrophy: Aki Ko - Neurology Live

Thu, 28 Mar 2024
Santhera's vamorolone NDA receives priority review in China - Pharmaceutical Business Review

Tue, 26 Mar 2024
Why Alzheimer's Drug Approval Delay? $3 Billion in DMD Gene Therapy; ADHD Prevalence - Medpage Today

Tue, 26 Mar 2024
FDA approves oral Duvyzat for Duchenne muscular dystrophy - Medical Xpress

Mon, 25 Mar 2024
FDA Approves Oral Nonsteroidal Treatment, Duvyzat, to Treat DMD - Genetic Engineering & Biotechnology News

Fri, 22 Mar 2024
Duvyzat, a Nonsteroidal Treatment for Duchenne Muscular Dystrophy, Gets FDA Approval - Monthly Prescribing Reference

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Neutral
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Neutral
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Neutral
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
Sector:
Industry:
Shares Out 0 (M)
Shares Float 0 (M)
Held by Insiders 0 (%)
Held by Institutions 0 (%)
Shares Short 0 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS 0
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) 0 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 0 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)
Stock Valuations
PE Ratio 0
PEG Ratio 0
Price to Book value 0
Price to Sales 0
Price to Cash Flow 0
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android